Scarica l'app Stockscreener
29.27
1.65%
-0.48
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALKS Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$29.75
Aprire:
$29.73
Volume 24 ore:
289.17K
Relative Volume:
0.17
Capitalizzazione di mercato:
$4.83B
Reddito:
$1.51B
Utile/perdita netta:
$333.35M
Rapporto P/E:
15.01
EPS:
1.95
Flusso di cassa netto:
$315.22M
1 W Prestazione:
+4.07%
1M Prestazione:
+11.98%
6M Prestazione:
-16.23%
1 anno Prestazione:
+4.69%
Intervallo 1D:
$29.22
$29.73
Intervallo di 1 settimana:
$28.11
$29.96
Portata 52W:
$25.56
$36.45
Alkermes Plc Stock (ALKS) Company Profile
Nome
Alkermes Plc
Settore
Telefono
00-353-1-772-8000
Indirizzo
CONNAUGHT HOUSE, DUBLIN 4
Confronta ALKS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
29.27 | 4.64B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
155.66 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.27 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.715 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.48 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
309.29 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-15 | Iniziato | Goldman | Buy |
| 2025-06-17 | Aggiornamento | UBS | Neutral → Buy |
| 2025-05-28 | Iniziato | Needham | Buy |
| 2025-03-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | Aggiornamento | UBS | Sell → Neutral |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-11-05 | Aggiornamento | Stifel | Hold → Buy |
| 2024-06-17 | Iniziato | TD Cowen | Buy |
| 2024-03-19 | Iniziato | Robert W. Baird | Outperform |
| 2024-02-20 | Downgrade | UBS | Neutral → Sell |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-10-24 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-10-17 | Iniziato | UBS | Neutral |
| 2022-11-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-08-16 | Iniziato | Piper Sandler | Neutral |
| 2022-04-22 | Ripresa | Goldman | Buy |
| 2022-04-20 | Iniziato | Goldman | Buy |
| 2022-01-27 | Aggiornamento | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | Iniziato | Citigroup | Neutral |
| 2021-10-07 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-09-02 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-10-15 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-07-30 | Downgrade | Goldman | Neutral → Sell |
| 2020-02-14 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | Reiterato | H.C. Wainwright | Neutral |
| 2020-02-14 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2020-01-31 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | Aggiornamento | Goldman | Sell → Neutral |
| 2019-05-31 | Iniziato | H.C. Wainwright | Neutral |
| 2019-05-01 | Downgrade | Citigroup | Buy → Neutral |
| 2018-12-19 | Downgrade | Goldman | Neutral → Sell |
| 2018-12-14 | Iniziato | Wolfe Research | Underperform |
| 2018-12-13 | Downgrade | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | Iniziato | Piper Jaffray | Neutral |
| 2018-08-07 | Iniziato | Stifel | Hold |
| 2018-06-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | Aggiornamento | Citigroup | Neutral → Buy |
| 2018-05-11 | Iniziato | BofA/Merrill | Buy |
Mostra tutto
Alkermes Plc Borsa (ALKS) Ultime notizie
After culling 90% of staff, Waltham biotech finds buyer - NBC Boston
Opioid Use Disorder Market: Generated Opportunities and Future Scope by 2032 | Indivior PLC, Alkermes, Orexo AB - openPR.com
Chart Analysts Warn of Resistance Near Alkermes plc PriceWeekly Market Outlook & Community Driven Trade Alerts - kangso.co.kr
Will Lowered Earnings Forecasts Shift Alkermes' (ALKS) Valuation Story or Reinforce Investor Caution? - simplywall.st
Price Floor Holding on Alkermes plc — Rebound PossibleQuarterly Portfolio Review & Daily Profit Maximizing Trade Tips - 선데이타임즈
Visual analytics tools that track Alkermes plc performance2025 Winners & Losers & Daily Growth Stock Investment Tips - Newser
Visual trend scoring systems applied to Alkermes plcJuly 2025 Update & Weekly Stock Breakout Alerts - Newser
Intraday pattern recognizer results for Alkermes plcJuly 2025 Summary & Stock Timing and Entry Methods - Newser
What’s the recovery path for long term holders of Alkermes plcGap Down & Safe Entry Point Alerts - Newser
Investors Don't See Light At End Of Alkermes Plc's (NASDAQ:ALKS) Tunnel - 富途牛牛
Is Alkermes plc stock influenced by commodity prices2025 Trading Volume Trends & Pattern Based Trade Signal System - thegnnews.com
Charles Schwab Investment Management Inc. Sells 21,558 Shares of Alkermes plc (NASDAQ:ALKS) - Defense World
PNC Financial Services Group Inc. Has $408,000 Stock Holdings in Alkermes plc (NASDAQ:ALKS) - Defense World
Vanguard Group Inc. Sells 283,511 Shares of Alkermes plc (NASDAQ:ALKS) - Defense World
Live Scanner Shows Breakout on Alkermes plcMarket Surge Signal for Swing Traders Triggered - metal.it
Is Alkermes plc in a long term uptrendWealth Leverage Stock List - mustnews.co.kr
Avantax Advisory Services Inc. Makes New $246,000 Investment in Alkermes plc (NASDAQ:ALKS) - Defense World
BlackRock increases stake in Alkermes to 17% - Investing.com India
BlackRock increases stake in Alkermes to 17% By Investing.com - Investing.com Nigeria
Alkermes plc Ireland - AD HOC NEWS
Alkermes plc Included in Top Momentum ScanInvestment Strategy Designed for Capital Protection - metal.it
Chondrosarcoma Market: Epidemiology, Pipeline Products, - openPR.com
Alkermes plc Announces Pricing of New Term Loans - AOL.com
HC Wainwright Brokers Boost Earnings Estimates for Alkermes - Defense World
What markets is AAON Inc. expanding into Is Alkermes plc stock a good long term investment optionBuild a diversified portfolio for steady growth - Jammu Links News
What is the dividend policy of Alkermes plc stockUnmatched market gains - Jammu Links News
Is Alkermes plc a growth stock or a value stockInvest smarter with expert trading signals - Jammu Links News
What makes Alkermes plc stock price move sharplyInvest confidently with professional advice - Jammu Links News
Is Alkermes plc stock overvalued or undervaluedGet exclusive access to expert stock recommendations - Jammu Links News
Alkermes Q2 Earnings Beat Estimates, Proprietary Drugs Aid Sales - MSN
What catalysts could drive Alkermes plc stock higher in 2025Invest confidently with professional advice - Jammu Links News
Should I hold or sell Alkermes plc stock in 2025Get expert analysis on top stock picks - Jammu Links News
Needham & Company LLC Reaffirms "Buy" Rating for Alkermes (NASDAQ:ALKS) - MarketBeat
How does Alkermes plc generate profit in a changing economyBuild capital through low-risk investments - Jammu Links News
What are analysts’ price targets for Alkermes plc in the next 12 monthsAchieve rapid portfolio growth with expert guidance - Jammu Links News
What are the technical indicators suggesting about Alkermes plcDiscover investment plans that deliver results - Jammu Links News
How strong is Alkermes plc company’s balance sheetUnlock powerful portfolio optimization tools - Jammu Links News
What markets is Alkermes plc expanding into Is ASLE stock a good long term investment optionBuild a portfolio that outperforms consistently - Jammu Links News
Alkermes Reports Q2 2025 Financial Results, Reiterates Expectations and Highlights Positive Clinical Study Results - AInvest
ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alkermes plc To Contact The Firm - ACCESS Newswire
Alkermes shares climb 5% following Q2 earnings and revenue beat - MSN
(07/31/25) ALKS: Positive Narcolepsy Drug Trial Puts this Biotech Name in F - moneyshow.com
Alkermes anticipates record proprietary product sales above $1B for 2025 as orexin pipeline advances - MSN
Alkermes: A More Than Solid Quarter (NASDAQ:ALKS) - Seeking Alpha
Alkermes stock price target raised to $42 from $40 at RBC Capital - Investing.com Nigeria
Alkermes plc (NASDAQ:ALKS) Q2 2025 Earnings Call Transcript - Insider Monkey
Alkermes Beat Expectations With A Strong Second Quarter - Finimize
Schizophrenia Drugs Market Exclusive Report with Detailed - openPR.com
Alkermes PLC (ALKS) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Alkermes: Q2 Earnings Snapshot - Norwalk Hour
Alkermes Reports Strong Q2 2025 Financial Results - TipRanks
Alkermes Plc Azioni (ALKS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Alkermes Plc Azioni (ALKS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Nichols Christian Todd | SVP, Chief Commercial Officer |
Jun 10 '25 |
Sale |
31.09 |
3,334 |
103,654 |
86,208 |
0.81%
0.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):